Advertisement

Control of Drug-Resistant TB

  • Fan Zhang
  • Wei-ye Yu
  • Hong-Jun Li
  • Chun-fa Song
  • Zheng Yang
  • Bu-dong Chen
  • Pu-Xuan Lu
  • Tao Chen
  • Guo-fang Deng
  • Le-cai Ji
  • Qiu-ting Zheng
Chapter

Abstract

Drug-resistant TB (DR-TB) refers to the infection of Mtb that is resistant to at least one anti-tuberculosis drug. The occurrence of DR-TB is caused by non-standardized treatment and/or insufficient management of patient with TB. Most of initially treated patient with non DR-TB can be cured by regular treatment of first-line anti-tuberculosis drug for 6 months. But inappropriate medication of anti-tuberculosis drugs (such as intermittent medication or inappropriate dosage) or early retrieval of anti-tuberculosis drug can induce resistance to anti-tuberculosis drug. And Mtb resistant to anti-tuberculosis drug further causes spread of DR-TB. The spread of drug-resistant Mtb in patients with DR-TB is an important way for spread of DR-TB. The prevalence and spread of drug-resistant Mtb present challenges to the global TB control. Especially along with the formation of global village, diversified flowing of populations for business, travelling, and purchase aggravates the prevalence of DR-TB.

References

  1. 1.
    World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis: 2006. WHO/HTM/TB/2006.361. Geneva: World Health Organization; 2006.Google Scholar
  2. 2.
    World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/2014.11. Geneva: World Health Organization; 2014.Google Scholar
  3. 3.
    WHO/IUATLD. Global Project on Anti-tuberculosis Drug Resistance Surveillance. Anti-tuberculosis drug resistance in the world. Third report. Geneva: WHO; 2004. p. 343.Google Scholar
  4. 4.
    Tang SJ, Xu SF, Li L. Drug-resistant tuberculosis. Beijing: People’s Medical Publishing House; 2014. p. 126–287.Google Scholar
  5. 5.
    Gao Q, Mei J. Spread is the main reason for high incidence of drug-resistant TB in China. Chin J Antituberculosis. 2015;37(11):1091–6.Google Scholar
  6. 6.
    Wang ZY. Recent development of studies on drug-resistant TB. Inf Infect Dis. 2018;31(1):19–23.Google Scholar
  7. 7.
    World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/2018.09. Geneva: World Health Organization; 2018.Google Scholar
  8. 8.
    World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/2017.10. Geneva: World Health Organization; 2017.Google Scholar
  9. 9.
    Ministry of Health, P. R. China. Compiled data on the national epidemiological sampling survey of TB in 1979; 1981.Google Scholar
  10. 10.
    Ministry of Health, P. R. China. Compiled data on the national epidemiological sampling survey of TB in 1984/1985; 1988.Google Scholar
  11. 11.
    Ministry of Health, P. R. China. Compiled data on the national epidemiological sampling survey of TB in 1990; 1992.Google Scholar
  12. 12.
    Ministry of Health, P. R. China. Compiled data on the national epidemiological sampling survey of TB in 2000; 2002.Google Scholar
  13. 13.
    Ministry of Health, P. R. China. Report on the national epidemiological sampling survey of TB in 2010; 2012.Google Scholar
  14. 14.
    Gao Q, Mei J. Spread is the main reason for high prevalence of DR-TB in China. Chin J Antituberculosis. 2015;37(11):1091–6.Google Scholar
  15. 15.
    Gao Q, Yang CG. Recent spread of TB in China and strategies for its control. J Tuberc Lung Health. 2017;6(13):193–8.Google Scholar
  16. 16.
    Yang HJ. Present tuberculosis control in migrating population. Med Inf. 2014;2014(19):642–3.Google Scholar
  17. 17.
    Lu W, Fu YY. Sustainable development of drug resistant TB control in China. J Tuberc Lung Health. 2016;5(4):262–6.Google Scholar
  18. 18.
    Zhou XJ. Drug resistant TB and its treatment strategies. West Med. 2017;29(1):141–4.Google Scholar
  19. 19.
    Bu QB. Epidemiology of pulmonary TB and its control measures. Healthcare Nutr China. 2015;25(10):58–9.Google Scholar
  20. 20.
    Kliiman K, Altraja A, Tang SJ, et al. Factors predicting failed treatment for multidrug resistant TB and extensive drug resistant TB. Chin J Tuberc Respir. 2009;32(8):563.Google Scholar
  21. 21.
    Du JH, Liu JC, Wang AM, et al. Research developments on drug resistant TB and its impact factors. Med Equip China. 2016;2016(s1):144.Google Scholar
  22. 22.
    Yang HJ. Present TB control in migrating population. Med Inf. 2014;2014(19):42–643.Google Scholar
  23. 23.
    Zhang T, Xi MX. Evolvement of directly observed treatment for patients with pulmonary TB. Pract Prev Med. 2017;2017(03):382–5.Google Scholar
  24. 24.
    Zhao YL, Li L, Zhou XH. Diagnosis of tuberculosis: part I. China Med News. 2006;21(10):14–5.Google Scholar
  25. 25.
    Zhao YL, Shang M. Laboratory diagnosis of tuberculosis in China. Chin J Lab Med. 2007;30(7):725–58.Google Scholar
  26. 26.
    Steingart KR, Ng V, Henry M, et al. Sputum processing methods to improve the sensitivity of smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis. 2006;6(10):664–74.PubMedGoogle Scholar
  27. 27.
    Yang XJ. Acid-fast staining for detection of bacillus: a comparative study. J Qiannan Med Coll Nat. 2008;21(1):6–7.Google Scholar
  28. 28.
    Alisjahbana B, Van Crevel R, Danusantoso H, et al. Better patient instruction for sputum sampling can improve microscopic tuberculosis diagnosis. Int J Tuberc Lung Dis. 2005;9(7):814–7.PubMedGoogle Scholar
  29. 29.
    Hirooka T, Higuchi T, Tanaka N, et al. [The value of proper sputum collection instruction in detection of acid-fast bacillus]. Kekkaku. 2004;79(2):33–7.Google Scholar
  30. 30.
    Guo J, Fan H, Kang M. Laboratory test for rapid detection of Mycobacterium tuberculosis. Int J Lab Med. 2006;27(9):807–8.Google Scholar
  31. 31.
    Steingart K R, Schiller I, Horne D J, et al. Xpert(R) MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev. 2014(1):CD009593.Google Scholar
  32. 32.
    Safianowska A, Walkiewicz R, Nejman-Gryz P, et al. [Diagnostic utility of the molecular assay GenoType MTBC (HAIN Lifesciences, Germany) for identification of tuberculous mycobacteria]. Pneumonol Alergol Pol. 2009;77(6):517–20.Google Scholar
  33. 33.
    Sun FS, Wu HN, Gu HM. Research developments on control of drug resistant tuberculosis. Med Rev. 2018;2018(1):86–9.Google Scholar
  34. 34.
    Yang SL, Bu HL, Fan MB. Drug sensitivity test by BACTEC-MGIT 960 and Roche proportional method: a comparative study. Clin Pract. 2015;2015(12):919–21.Google Scholar
  35. 35.
    Zheng Y, Xia H, Zhao YL. Sensitivity test of Mycobacterium tuberculosis to first-line and second-line anti-tuberculosis drugs by TREK Sensititre MYCOTB. Chin J Antituberculosis. 2015;37(6):597–602.Google Scholar
  36. 36.
    Li H, Wang SH, Zhu YK. Diagnosis of multidrug-resistant tuberculosis based on two different molecular biological detections for multidrug-resistant genes. Chin J Health Lab Technol. 2015;25(15):2567–9.Google Scholar
  37. 37.
    Makinen J, Marttila HJ, Marjamaki M, et al. Comparison of two commercially available DNA line probe assays for detection of multidrug-resistant Mycobacterium tuberculosis. J Clin Microbiol. 2006;44(2):350–2.PubMedPubMedCentralGoogle Scholar
  38. 38.
    Committee of Infectious Disease Radiology in Branch of Radiology, Chinese Medical Society. Consensus on imaging diagnosis for grading of pulmonary tuberculosis. Electron J Emerg Infect Dis. 2018;3(2):118–27.Google Scholar
  39. 39.
    Zhang ZX, Ren GY, Tan YC, et al. CT scanning demonstrations of Rifamycin resistant pulmonary tuberculosis. Guide China Med. 2015;13(25):64–5.Google Scholar
  40. 40.
    Chen GM, Cheng GX, Zhu SQ, et al. CT scanning demonstration of initially treated patients with single drug resistant pulmonary tuberculosis. Electron J Emerg Inf Dis. 2018;3(2):111–4.Google Scholar
  41. 41.
    Li CH, Lv SX, Wang HQ, et al. CT scanning demonstrations of multidrug resistant pulmonary tuberculosis and their relationship with CD4 cell count. Chin J Antituberculosis. 2017;39(6):597–603.Google Scholar
  42. 42.
    Wang YX, Chung MJ, Skrahin A, et al. Literature analysis on radiological demonstrations related to multidrug resistant pulmonary tuberculosis. Electron J Emerg Inf Dis. 2018;3(3):244–53.Google Scholar
  43. 43.
    Yu WY, Tan WG, Zhong FX, et al. Categorization and typing of drug resistant pulmonary tuberculosis and their diagnostic imaging. Electron J Emerg Inf Dis. 2019;4(1):52–6.Google Scholar
  44. 44.
    Chinese Anti-tuberculosis Society. 2015 Guideline for chemical treatment of drug resistant tuberculosis. Chin J Antituberculosis. 2015;37(5):421–69.Google Scholar
  45. 45.
    World Health Organization. WHO guideline for treatment of isoniazid resistant tuberculosis: supplement to the WHO guideline for treatment of drug resistant tuberculosis. Geneva: World Health Organization; 2018.Google Scholar
  46. 46.
    Companion handbook to the 2014 WHO guidelines for the programmatic management of drug resistant tuberculosis. Chin J Antituberculosis. 2015;37(7):800–2.Google Scholar
  47. 47.
    Aung KJ, Van Deun A, Declercq E, et al. Successful ‘9-month Bangladesh regimen’ for multidrug-resistant tuberculosis among over 500 consecutive patients. Int J Tuberc Lung Dis. 2014;18(10):1180–7.PubMedGoogle Scholar
  48. 48.
    WHO. Rapid communication: key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB). Geneva: World Health Organization; 2018.Google Scholar
  49. 49.
    World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis. 2016 update. Geneva: World Health Organization; 2016.Google Scholar
  50. 50.
    Dai ZC, Xiao DL, Wan LY. The history of anti-tuberculosis in China. Beijing: People’s Medical Publishing House; 2013. p. 58.Google Scholar
  51. 51.
    World Health Organization. Global tuberculosis report 2014. Geneva: World Health Organization; 2014.Google Scholar
  52. 52.
    Zhou L, Xue X, Wang F, et al. Implementation of tuberculosis management. Chin J Antituberculosis. 2013;35(2):120–4.Google Scholar
  53. 53.
    Disease Control Bureau of Health Ministry, Medial Administration Department of Health Ministry, Center for Disease Control, China. Technical guideline for implementation of tuberculosis control planning in China. Beijing: Peking Union Medical College Press; 2009. p. 20.Google Scholar
  54. 54.
    Chen J, Wang Y, Hu DY. Effects of directly observed treatment on tuberculosis control. Med Foreign Countries: Social Med. 2005;22(4):166–70.Google Scholar
  55. 55.
    Huang CY, Song JD, Li GZ, et al. DOTS in management of outpatients with sputum smear positive pulmonary tuberculosis. Popul Health. 2014;8(24):114.Google Scholar
  56. 56.
    Jiang L. Research developments on compliance of patients with tuberculosis to medication. Inf Infect Dis. 2012;25(1):55–7.Google Scholar
  57. 57.
    Ma HX, Wang JY. Effects of health education on patients with pulmonary tuberculosis. China Med Innov. 2012;9(13):147–8.Google Scholar
  58. 58.
    Guo WR. Family based DOT strategy in 155 patients with sputum smear positive tuberculosis. Chin J Antituberculosis. 2010;32(4):202–3.Google Scholar
  59. 59.
    Wen K, Ma J. Effects of family based DOT strategy on compliance of initially treated patients with sputum smear positive pulmonary tuberculosis. China Med Innov. 2015;12(3):124–6.Google Scholar
  60. 60.
    Zhu J. On nursing of patients with pulmonary tuberculosis. China Med Innov. 2012;9(1):85–6.Google Scholar
  61. 61.
    Xu GB, Liu FY, Feng QM, et al. New strategy on tuberculosis control in rural areas of Guangxi Zhuang autonomous region of China. Chin J Antituberculosis. 2011;45(1):30–5.Google Scholar
  62. 62.
    Wang YX. Community based DOT strategy in 56 patients with pulmonary tuberculosis. Anhui Med. 2012;16(11):1720–1.Google Scholar
  63. 63.
    Li JW, Wu WF, Han DL. Comprehensive survey on pulmonary tuberculosis in peasant workers. China Med Innov. 2011;8(2):26–8.Google Scholar
  64. 64.
    World Health Organization. Public-private mix for DOTS—global progress. Geneva: World Health Organization; 2004. p. 2–9.Google Scholar
  65. 65.
    Lal SS, Sahu S, Wares F, et al. Intensified scale-up of public-private mix: a systems approach to tuberculosis care and control in India. Int J Tuberc Lung Dis. 2011;15(1):97–104.PubMedGoogle Scholar
  66. 66.
    Haq Z, Khan W, Scita A. Promoting public-private mix for TB-DOTS: a multi-country study from the WHO Eastern Mediterranean Region. East Mediterr Health J. 2012;18(5):410–6.PubMedGoogle Scholar
  67. 67.
    Technical Guidance Team of the national epidemiological sampling survey for tuberculosis. Report on 2000 National Epidemiological Sampling Survey on tuberculosis. Chin J Antituberculosis. 2002;24(2):86–96.Google Scholar
  68. 68.
    Zhu LY, Zhang QY, Zhong CQ, et al. Implementation of PPM-DOTS tuberculosis control program in urban area of Lianyungang, China. J Nanjing Med Univ (Nat Sci). 2008;28(12):1690–3.Google Scholar
  69. 69.
    Yang HL, Bao CL, Bai LQ, et al. Telephone based DOTS and traditional DOTS in rural areas of Hunan province, China: a comparative study. Chin J Antituberculosis. 2011;33(10):646–50.Google Scholar
  70. 70.
    Lu F, Xu H, Fu J. Effects of mobile phone text message based DOTS on compliance of patients with pulmonary tuberculosis. Chin J Antituberculosis. 2012;34(10):651–4.Google Scholar
  71. 71.
    Bao CL, Bai LQ, Tang Y, et al. Effects of telephone based DOTS and traditional DOTS on therapeutic efficacy of pulmonary tuberculosis. Pract Prev Med. 2012;19(12):1803–6.Google Scholar
  72. 72.
    Xi MX, Qin Q, Zeng YL, et al. Application of internet based collaborative nursing in management of patients with MHD. J Changsha Univ. 2015;29(1):58–61.Google Scholar

Copyright information

© People's Medical Publishing House, PR of China 2020

Authors and Affiliations

  • Fan Zhang
    • 1
  • Wei-ye Yu
    • 2
  • Hong-Jun Li
    • 3
  • Chun-fa Song
    • 1
  • Zheng Yang
    • 4
  • Bu-dong Chen
    • 5
  • Pu-Xuan Lu
    • 6
  • Tao Chen
    • 7
  • Guo-fang Deng
    • 7
  • Le-cai Ji
    • 4
  • Qiu-ting Zheng
    • 4
  1. 1.Shenzhen Nanshan Center for Chronic Disease ControlShenzhenChina
  2. 2.Department of TuberculosisThe Shenzhen Center for Chronic Disease ControlShenzhenChina
  3. 3.Department of Radiology, Beijing You’an HospitalCapital Medical UniversityBeijingChina
  4. 4.Shenzhen Center for Chronic Disease ControlShenzhenChina
  5. 5.Department of Radiology, Beijing Ditan HospitalCapital Medical UniversityBeijingChina
  6. 6.Department of RadiologyThe Shenzhen Center for Chronic Disease ControlShenzhenChina
  7. 7.The Third People’s Hospital of ShenzhenShenzhenChina

Personalised recommendations